GlassScriptPhysician profile
Diana Lebron
NPI 1205916608
$2,500.17
in general payments reported to CMS, 2019-2025
17 companies · $327 in 2025
The $327 reported for 2025 was more than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,510 · 2020: $99.39 · 2021: $94.99 · 2022: $333 · 2023: $73.78 · 2024: $60.75 · 2025: $327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $462.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $461.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $1,293.86 | 2019 | |
| Biomarin Pharmaceutical INC. | $334.45 | 2020-2025 | |
| Greenwich Biosciences, INC. | $159.76 | 2019-2021 | |
| Boston Scientific Corporation | $149.47 | 2023-2025 | Versacross Steerable Access Solution, Watchman Access System, Versacross Access Solution |
| Corium, LLC | $91.94 | 2025 | Azstarys |
| Ucb, INC. | $86.96 | 2019-2022 | |
| Neurelis, INC. | $83.70 | 2022 | |
| Collegium Pharmaceutical, INC. | $62.58 | 2025 | Jornay Pm |
| Sunovion Pharmaceuticals INC. | $60.48 | 2019 | |
| Astellas Pharma US INC | $37.22 | 2025 | |
| Upsher-Smith Laboratories LLC | $24.29 | 2019 | |
| Ironshore Pharmaceuticals INC. | $23.04 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $21.53 | 2021 | |
| Mallinckrodt Enterprises LLC | $18.96 | 2019 | |
| Aquestive Therapeutics, INC. | $18.57 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $17.31 | 2020 | |
| Supernus Pharmaceuticals, INC. | $16.05 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diana Lebron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.